Pfizer

Anti-IL-4/IL-13/IL-33 biologic in Phase 2 for Atopic Dermatitis, targeting inflammatory skin disease.

Biologic investigational drug for lupus in phase 1, current development; anti-CXCR5.

TNFSF15 Blocker biologic for treatment of Ulcerative Colitis in Phase 2

TYK2/JAK1 inhibitor for Hidradenitis Suppurativa, Ulcerative Colitis, Crohn's Disease, Vitiligo, Psoriatic Arthritis, Alopecia Areata, Lupus, Topical Atopic Dermatitis, and Topical Psoriasis.

SIK inhibitor in Phase 1 for Ulcerative Colitis, targeting autoimmune disease.

TYK2 inhibitor for Psoriasis and Ulcerative Colitis.

CD1a inhibitor biologic for treatment of Atopic Dermatitis in Phase 1

PD-1xVEGF Bispecific Antibody for unresectable locally advanced or metastatic hepatocellular carcinoma.

Biologic investigational drug for inflammatory bowel disease in phase 2, current development; p40/TL1a bispecific.

Biologic investigational drug for pulmonary arterial hypertension in phase 2, current development; anti-BMP9; orphan drug in U.S.

EGFR-targeted bispecific gamma delta T-cell engager for advanced solid tumors.

CD228V directed antibody-drug conjugate for advanced melanoma and other solid tumors.

Immunostimulatory Drug Conjugate (ISAC) targeted to PD-L1 with a TLR7 agonist payload for advanced solid tumors.

Non-fucosylated CD70-directed antibody for myelodysplastic syndrome and acute myeloid leukemia.

CEACAM5-directed antibody-drug conjugate for advanced solid tumors.

Topical PDE4 Inhibitor for treatment of Atopic Dermatitis in Phase 2

Mesothelin-targeted antibody-drug conjugate for advanced solid tumors.

Selective inhibitor of epigenetic modifiers KAT6A, KAT6B and KAT7 for advanced solid tumors.

Integrin beta-6-directed antibody-drug conjugate for non-muscle invasive bladder cancer.

A potential biosimilar to Neulasta® (pegfilgrastim) for Neutropenia in patients undergoing cancer chemotherapy (Biosimilar) (U.S., E.U.).

CD25V directed antibody-drug conjugate for advanced solid tumors.

Growth Differentiation Factor 15 (GDF15) Monoclonal Antibody for Cachexia (Biologic) in Phase 1

Undisclosed mechanism in development for ulcerative colitis.

CD30-directed antibody TOPO1 drug conjugate for advanced solid tumors.

A potential biosimilar to Rituxan® /MabThera® (rituximab) for Follicular Lymphoma (Biosimilar) (E.U.).

SARS-CoV-2 3CL protease inhibitor (oral COVID-19 treatment) for COVID-19 Infection (FAST TRACK – U.S.).

Glycoprotein-NMB directed antibody drug conjugate for advanced solid tumors.

Integrin alpha-V/beta-8 antagonist for advanced solid tumors.

A potential biosimilar to Humira® (adalimumab) for Rheumatoid Arthritis (Biosimilar) (E.U.).

Selective KRAS inhibitor for advanced solid tumors.

Biologic investigational drug for atopic dermatitis in phase 1, current development.

Acetyl CoA-Carboxylase (ACC) Inhibitor for Non-Alcoholic Steatohepatitis (NASH) with Liver Fibrosis (FAST TRACK).

Biologic investigational drug for nephropathy in phase 1, current development.

Small molecule investigational drug for atopic dermatitis in phase 1, current development; STAT6 inhibitor.

A combination drug containing ceftazidime, a third-generation cephalosporin antibiotic, and avibactam, a novel non-β-lactam β-lactamase inhibitor, approved for treatment of complicated intra-abdominal infection, complicated urinary tract infection, and hospital-acquired pneumonia.

DiacylglycerolO-Acyltransferase (DGAT2) Inhibitor for Non-Alcoholic Steatohepatitis (NASH).

ACCi and DGAT2 Combination for Non Alcoholic Steatohepatitis (NASH).

Glucagon-like peptide 1 receptor (GLP-1R) Agonist for Diabetes Mellitus-Type 2 and Obesity in Phase 1

CDK 4,6 Inhibitor for Pulmonary Arterial Hypertension.

Small molecule investigational drug for acne in phase 1, discontinued.

Small molecule investigational drug for hidradenitis suppurativa, chronic spontaneous urticaria, Crohn's disease, and ulcerative colitis in phase 2, current development; JAK3/TEC inhibitor.

Biologic investigational drug for hemophilia (pediatric inhibitor and non-inhibitor cohorts) in registration phase; breakthrough therapy and orphan drug in U.S.; anti-tissue factor pathway inhibitor.

A gene therapy candidate for severe hemophilia A, currently in Phase 3 clinical trial.

Human growth hormone agonist for adult growth hormone deficiency with orphan designation in the EU, in registration phase.

A compound for muscle invasive bladder cancer and locally advanced/metastatic urothelial carcinoma focusing on adverse event prevention, retreatment, clinical resistance, and combination strategies.

A Nectin-4 directed antibody-drug conjugate (ADC) approved for use in combination with PD-1 inhibitors as neoadjuvant and adjuvant treatment for muscle-invasive bladder cancer (MIBC) in adults ineligible for cisplatin chemotherapy.

An investigational gene therapy for the treatment of hemophilia B, currently in a pivotal Phase 3 clinical trial.

Biologic investigational drug for rheumatoid arthritis in phase 1, current development; IL-10.

Biologic for Rheumatoid Arthritis and Ulcerative Colitis (Product Enhancement).

LP.8.1-adapted monovalent COVID-19 vaccine approved by FDA for use in adults 65 years and older and individuals 5 through 64 years with high risk for severe COVID-19 outcomes.

A COVID-19 mRNA vaccine in a pre-filled syringe format for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older.

A COVID-19 mRNA vaccine indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in children 5 to 11 years of age and infants 6 months to 4 years of age, administered intramuscularly as a single dose of 0.3 mL or as a primary course of 2 doses for infants.

Abrocitinib tablets for prescription use, 100 mg strength, 30 count.

Integrin beta-6-directed antibody-drug conjugate for advanced solid tumors.

Treatment for 2L+ Non-squamous Metastatic Non-small Cell Lung Cancer in Be6A LUNG-01 study and 1L Non-small Cell Lung Cancer TPS All Comers.

AZTREONAM (aztreonam) pharmaceutical product by Pfizer.

Beta lactam/beta lactamase inhibitor for treatment of adult patients with cIAI, HAP/VAP, cUTI pyelonephritis and infections due to aerobic gram negative organisms in adult patients with limited treatment options.

COMIRNATY is a vaccine indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It is approved for use in individuals 5 years of age and older, including those with underlying conditions that put them at high risk for severe outcomes from COVID-19.

Pfizer/BioNTech COVID-19 vaccine booster authorized for individuals 65 years and older and certain high-risk groups aged 18-64; conditional marketing authorization in EMA for 18+ years; EUA for 5-11 years in U.S.

A pharmaceutical product formulated as a nanoform vaccine targeting the Omicron XBB.1.5 variant of Covid-19, marketed under the trade name Comirnaty.

A COVID-19 mRNA vaccine indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older. It is supplied as a multidose vial with a purple cap and must be diluted before use.

SARS-CoV-2 3CL protease inhibitor (oral COVID-19 treatment) for COVID-19 Infection (pediatric).

Paxlovid is a co-packaged oral treatment for COVID-19 consisting of nirmatrelvir and ritonavir tablets, indicated for adults at increased risk of severe disease progression.

A COVID-19 mRNA vaccine indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older and other age groups as specified.

A COVID-19 mRNA vaccine indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in children 5 to 11 years of age and infants 6 months to 4 years of age with specific dosing regimens.

Monthly Chronic Weight Management in Phase 2b VESPER-3 study and multiple other studies including weekly chronic weight management in obesity and type 2 diabetes mellitus.

Combination therapy for Chronic Weight Management in Phase 1/2 studies.

Exemestane tablets for prescription use, 25 mg strength, 30 count.

A COVID-19 mRNA vaccine in a multidose vial containing 6 doses of 0.3 mL each, with 15 micrograms of tozinameran and 15 micrograms of famtozinameran per dose, for active immunisation to prevent COVID-19 in individuals 12 years and older.

Bosutinib tablets for prescription use, 100 mg strength, 120 count.

Combination tablets of spironolactone and hydrochlorothiazide for prescription use, 25 mg/25 mg strength, 100 count.

Hydrocortisone tablets for prescription use, 10 mg strength, 100 count.

Combination tablets of quinapril HCl and hydrochlorothiazide for prescription use, 20 mg/25 mg strength, 90 count.

Combination tablets of diclofenac sodium and misoprostol for prescription use, 50 mg/200 mcg strength, 60 count.

Varenicline tablets for prescription use, 0.5 mg strength, packaged for 1 starting week and 3 subsequent weeks, 1x11 and 3x14 tablets.

Colestipol hydrochloride tablets for prescription use, 1 gm strength, 120 count.

Colestipol hydrochloride flavored granules for prescription use, 450 gm bottle.

Colestipol hydrochloride granules for prescription use, 500 gm bottle.

JAK1 Inhibitor for treatment of Atopic Dermatitis (PRIORITY REVIEW, BREAKTHROUGH – U.S., E.U.)

Anti-P-selectin biologic in Phase 3 for sickle cell disease with Rare Pediatric Disease and Orphan Drug designations in the U.S.

S1P inhibitor for Eosinophilic Esophagitis, Alopecia Areata, Crohn's disease, and Atopic Dermatitis (Phase 2).

An anti-IL-4/IL-13/TSLP biologic in Phase 2 for atopic dermatitis and asthma, with product enhancement focus for asthma.

Small molecule investigational drug for sickle cell disease in phase 3, current development; HbS polymerization inhibitor; orphan drug in U.S.

Combination of JAK3/TEC Inhibitor, IRAK4 Inhibitor, and JAK Inhibitor for treatment of Rheumatoid Arthritis in Phase 2

Investigational drugs that selectively block messaging pathways associated with inflammation, currently in clinical studies for treating inflammatory bowel disease (IBD).

Anti-IFN-β biologic in Phase 3 for Dermatomyositis and Polymyositis (Orphan in U.S.), Phase 2 for Lupus, targeting autoimmune diseases.

S1P inhibitor in Phase 2 for Crohn's disease and eosinophilic esophagitis.

Investigational anti-PD-1 monoclonal antibody in Phase 3 CREST trial combined with BCG for high-risk non-muscle invasive bladder cancer, showing improved event-free survival.

Treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

Biologic investigational drug for chronic obstructive pulmonary disease, asthma, and atopic dermatitis in phase 2, current development; anti-IL-4/ IL-13/ TSLP.

CD47-SIRPa fusion protein for hematological malignancies.

An investigational medicine that blocks TL1A, an inflammatory mediator linked to inflammatory bowel disease (IBD), currently being tested in IBD patients.

Treatment for 1L Metastatic Colorectal Cancer (Symbiotic-GI-03), 1L Endometrial Cancer, 1L Squamous / Non-squamous Non-small Cell Lung Cancer (Symbiotic-Lung-01), and 1L Metastatic Urothelial Cancer in combination with PADCEV.

Respiratory syncytial virus fusion inhibitor in Phase 3 for adults and Phase 2 for pediatric RSV infection treatment.

Tissue Factor-directed antibody-drug conjugate for recurrent or metastatic cervical cancer.

HER2-directed antibody-drug conjugate for locally advanced or metastatic solid tumors with HER2 expression.

infliximab-qbtx

PDE4 Inhibitor for treatment of Stasis Dermatitis in Phase 2

Biologic investigational drug for atopic dermatitis in phase 2, current development; anti-IL-4/ IL-13/ IL-33.

Bivalent respiratory syncytial virus (RSV) prefusion F (RSVpreF) vaccine for prevention of lower respiratory tract disease caused by RSV in individuals 18 through 59 years of age.

Treatment for 1-2L Metastatic Castration-resistant Prostate Cancer Post-abiraterone in MEVPRO-1 study.

Angiopoietin Like 3 (ANGPTL3) Antisense Oligonucleotide for Severe Hypertriglyceridemia, Reduction of Cardiovascular Risk in Phase 2

Evaluated in combination with fulvestrant for hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in patients previously treated with CDK 4/6 inhibitors, showing significant improvement in progression-free survival.

Vaccine candidate for Lyme Disease in collaboration with Valneva.

A therapeutic candidate designed to specifically inhibit CDK4 enzyme, currently in a Phase 3 clinical trial, aimed at treating metastatic breast cancer with potential for improved tolerability and efficacy.

glasdegib

pegfilgrastim-apgf

Beta lactam/Beta lactamase inhibitor in Phase 1 for complicated urinary tract infections including pyelonephritis.

CDK2 + CDK4 inhibitors for metastatic breast cancer.

gemtuzumab ozogamicin for injection

Combination of DGAT2 Inhibitor and Acetyl CoA-Carboxylase (ACC) Inhibitor for Non-alcoholic Steatohepatitis (NASH) with Liver Fibrosis in Phase 2

Used in combination with lenalidomide and a rituximab product for treatment of relapsed or refractory large B-cell lymphoma including diffuse large B-cell lymphoma and high-grade B-cell lymphoma.

axitinib

A biosimilar to Humira® (adalimumab), for the treatment of certain patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease, ulcerative colitis and plaque psoriasis (U.S.).

Nerve Growth Factor Inhibitor for OA Signs and Symptoms (FAST TRACK), Chronic Low Back Pain (FAST TRACK), Cancer Pain (Biologic).

PDE4 Inhibitor for Atopic Dermatitis (E.U.).

taliglucerase alfa

Gwt1 inhibitor for invasive fungal infections.

MEK brain penetrant inhibitor for advanced solid tumors.

A combination vaccine product candidate by Pfizer.

Active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups A, B, C, W, and Y, for use in individuals 10 through 25 years of age.

infliximab-dyyb

In combination with INLYTA (axitinib) for the first-line treatment of adult patients with advanced renal cell carcinoma (E.U.).

BRAF Class 1 and Class 2 inhibitor for advanced solid tumors.

filgrastim-aafi

KAT6 epigenetic modifier for metastatic breast cancer.

Tick-borne encephalitis (TBE) vaccine for active immunization to prevent TBE in individuals 1 year of age and older (U.S.)

Combination therapy for 1L HRRm Metastatic Castration-sensitive Prostate Cancer in TALAPRO-3 study.

Glucagon-like peptide 1 receptor (GLP-1R) Agonist for Diabetes Mellitus-Type 2 and Obesity in Phase 2

A compound for exploration in front-line treatment of acute lymphoblastic leukemia (ALL) including studies incorporating comparator to standard of care and expanding existing evidence.

SMO (smoothened) antagonist in combination with low-dose cytarabine (LDAC) for Acute Myeloid Leukemia (E.U.).

A tyrosine kinase inhibitor used in first-line combination therapy for HER2-positive metastatic breast cancer (MBC).

docetaxel injection

bortezomib

methotrexate

In combination with methotrexate for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (E.U.).

Combination of relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg for management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women

A compound for BRAF V600E/K mutant unresectable or metastatic melanoma and metastatic colorectal cancer, focusing on real world data, treatment sequencing, and resistance studies.

A PD-1 inhibitor used in combination with PADCEV for neoadjuvant and adjuvant treatment in muscle-invasive bladder cancer (MIBC).

meropenem for injection

A pharmaceutical product candidate by Pfizer.

Pneumococcal 20-valent Conjugate Vaccine for prevention of invasive disease and pneumonia caused by 20 Streptococcus pneumoniae serotypes in adults 18 years and older

Phase 3 PATINA trial showed addition to first-line maintenance therapy improved progression free survival in HR+, HER2+ metastatic breast cancer patients.

A suspension for intramuscular injection authorized under Emergency Use Authorization (EUA) for active immunization to prevent COVID-19 in individuals 5 through 11 years of age. Supplied in multiple dose vials with orange caps and labels with orange borders, requiring dilution before use.

25-valent pediatric vaccine candidate for Pneumococcal Infection.

A pharmaceutical product candidate by Pfizer.

A pharmaceutical product candidate by Pfizer.

A pharmaceutical product candidate by Pfizer.

A drug for the management of ATTR Cardiac Amyloidosis, focusing on early identification, follow-up, and real-world efficacy and safety in clinical settings.

daptomycin

fluconazole

Pfizer's COVID-19 vaccine based on mRNA technology.

Treatment for Chronic Migraine and Redosing for Acute Treatment of Migraine.

A compound used in metastatic renal cell carcinoma (RCC) with focus on immuno-oncology combinations, sequencing, and real world data studies.

Oral GnRH receptor antagonist combination with estradiol and norethindrone acetate for Endometriosis (U.S.) and contraceptive efficacy

ATGAM® (lymphocyte immune globulin, anti-thymocyte globulin [equine] sterile solution) pharmaceutical product by Pfizer.

AZITHROMYCIN (azithromycin) pharmaceutical product by Pfizer.

Ampicillin and sulbactam pharmaceutical product by Pfizer.

piperacillin and tazobactam

A pharmaceutical product candidate by Pfizer.

A compound for metastatic non-small cell lung cancer (mNSCLC) focusing on real world evidence studies in first-line EGFR mutant mNSCLC.

fosphenytoin sodium injection

A pharmaceutical product candidate by Pfizer.

apixaban

medroxyprogesterone acetate injectable suspension

A pharmaceutical product for the treatment of short stature, compared with daily growth hormone treatment, focusing on clinical effects, adherence, and novel monitoring strategies.

AZULFIDINE® (sulfasalazine, USP) pharmaceutical product by Pfizer.

AMIDATE™ (etomidate) pharmaceutical product by Pfizer.

ALTACE® (ramipril) pharmaceutical product by Pfizer.

ARGATROBAN (argatroban injection, solution) pharmaceutical product by Pfizer.

venlafaxine hydrochloride

Atracurium besylate pharmaceutical product by Pfizer.

Aminocaproic acid pharmaceutical product by Pfizer.

Acetylcysteine solution pharmaceutical product by Pfizer.

AMINOPHYLLINE (aminophylline) pharmaceutical product by Pfizer.

Atropine sulfate pharmaceutical product by Pfizer.

Clindamycin palmitate hydrochloride flavored granules for oral solution, 75 mg/5 mL strength, 100 mL bottle.

Ammonium chloride pharmaceutical product by Pfizer.

Methsuximide capsules for prescription use, 300 mg strength, 100 count.

Misoprostol tablets for prescription use, 100 mcg strength, 60 count.

dextrose

Verapamil hydrochloride extended release tablets for prescription use, 180 mg strength, 100 count.

Spironolactone tablets for prescription use, 100 mg strength, 100 count.

Quinapril HCl tablets for prescription use, 10 mg strength, 90 count.

A sterile, pyrogen-free powder for reconstitution used as an antibacterial agent for intramuscular, continuous intravenous drip, intrapleural or other local infusion, and intrathecal administration.

COLESTID is a pharmaceutical product by Pfizer available in granules and tablets forms, intended for cholesterol management.